Sorrento Therapeutics Inc (SRNE)

[dia76ca]

Sorrento has over 50 drug programs!
Phase 3 or close to EUA (11 programs)
1. Abivirtinib NSCLC
2. PD-L1 partnered
3. Erbitux biosimilar
4. Xolair biosimilar
5. Remicade biosimilar
6. SP-102 sciatica
7. RTX Osteo Arthritis
8. RTX cancer pain
9. Covi-Stix EUA application
10. Covi-Trace EUA application
11. Cynviloq (part of PSS lawsuit)

Phase 2 (11 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential
4. Covi-Track EUA pre-validation
5. PD-L1 partnered
6. Herceptin delivery partnered
7. Abivirtinib Lymphoma
8. Abivirtinib Covid 19
9. Abivirtinib prostate cancer ph.2 IND
10. Abivirtinib Lupus ph.2 IND
11. CD47 partnered

Phase 1, IND filed or pre-IND (28+ programs)
1. Seprehvec Oncolytic Virus
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T IND
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Covi-Drops ph.1
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1
17. TROP2 pre-IND partnered
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND

FUNDING? Sorrento has invested wisely and has 8.2 million shares of ImmunityBio, 20 million shares of Celularity and 35% of ImmuneOncia. These are worth many hundreds of millions and the PSS lawsuit will soon be settled with very large potential gains. And it has many attractive programs to partner for upfront, milestone and royalty payments! Huge portfolio AND huge assets!